Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region
The incidence of psoriasis in Africa and the Middle East (AfME) is high as in other regions and represents a significant problem for both dermatologists and patients. Psoriasis co-morbidities such as obesity, cardiovascular disease and psoriatic arthritis (PsA) are also particularly common in these...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-02-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2016.1183763 |
| _version_ | 1797684004923637760 |
|---|---|
| author | Anwar Al Hammadi Afaf Al-Sheikh Alfred Ammoury Samer Ghosn Paolo Gisondi Issam Hamadah Abdul-Ghani Kibbi Khalid Shirazy |
| author_facet | Anwar Al Hammadi Afaf Al-Sheikh Alfred Ammoury Samer Ghosn Paolo Gisondi Issam Hamadah Abdul-Ghani Kibbi Khalid Shirazy |
| author_sort | Anwar Al Hammadi |
| collection | DOAJ |
| description | The incidence of psoriasis in Africa and the Middle East (AfME) is high as in other regions and represents a significant problem for both dermatologists and patients. Psoriasis co-morbidities such as obesity, cardiovascular disease and psoriatic arthritis (PsA) are also particularly common in these regions and may be under-recognized and under-treated. Despite this, regional guidelines to aid physicians on the appropriate use of biologic agents in their clinical practice are limited. A group of expert dermatologists from across the AfME region were surveyed to help establish best practice across the region, alongside supporting data from the literature. Although biologics have significantly improved patient outcomes since their introduction, the results of this survey identified several unmet needs, including the lack of consensus regarding their use in clinical practice. Discrepancy also exists among AfME physicians concerning the clinical relevance of immunogenicity to biologics, despite increasing data across inflammatory diseases. Significant treatment and management of challenges for psoriasis patients remain, and a move towards individualized, tailored care may help to address these issues. The development of specific local guidelines for the treatment of both psoriasis and PsA could also be a step towards understanding the distinct patient profiles in these regions. |
| first_indexed | 2024-03-12T00:23:07Z |
| format | Article |
| id | doaj.art-78877ba0667040e68745f5d6e70cd532 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:23:07Z |
| publishDate | 2017-02-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-78877ba0667040e68745f5d6e70cd5322023-09-15T10:48:02ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532017-02-0128212913510.1080/09546634.2016.11837631183763Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East regionAnwar Al Hammadi0Afaf Al-Sheikh1Alfred Ammoury2Samer Ghosn3Paolo Gisondi4Issam Hamadah5Abdul-Ghani Kibbi6Khalid Shirazy7Rashid HospitalKing Abdulaziz Medical CitySt George Hospital University Medical CenterAmerican University of Beirut Medical CenterUniversity Hospital of VeronaKing Faisal Hospital and Research CentreAmerican University of Beirut Medical CenterPfizer IncThe incidence of psoriasis in Africa and the Middle East (AfME) is high as in other regions and represents a significant problem for both dermatologists and patients. Psoriasis co-morbidities such as obesity, cardiovascular disease and psoriatic arthritis (PsA) are also particularly common in these regions and may be under-recognized and under-treated. Despite this, regional guidelines to aid physicians on the appropriate use of biologic agents in their clinical practice are limited. A group of expert dermatologists from across the AfME region were surveyed to help establish best practice across the region, alongside supporting data from the literature. Although biologics have significantly improved patient outcomes since their introduction, the results of this survey identified several unmet needs, including the lack of consensus regarding their use in clinical practice. Discrepancy also exists among AfME physicians concerning the clinical relevance of immunogenicity to biologics, despite increasing data across inflammatory diseases. Significant treatment and management of challenges for psoriasis patients remain, and a move towards individualized, tailored care may help to address these issues. The development of specific local guidelines for the treatment of both psoriasis and PsA could also be a step towards understanding the distinct patient profiles in these regions.http://dx.doi.org/10.1080/09546634.2016.1183763biologicsco-morbiditiesguidelinesscreeningtreatment |
| spellingShingle | Anwar Al Hammadi Afaf Al-Sheikh Alfred Ammoury Samer Ghosn Paolo Gisondi Issam Hamadah Abdul-Ghani Kibbi Khalid Shirazy Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region Journal of Dermatological Treatment biologics co-morbidities guidelines screening treatment |
| title | Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region |
| title_full | Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region |
| title_fullStr | Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region |
| title_full_unstemmed | Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region |
| title_short | Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region |
| title_sort | experience and challenges for biologic use in the treatment of moderate to severe psoriasis in africa and the middle east region |
| topic | biologics co-morbidities guidelines screening treatment |
| url | http://dx.doi.org/10.1080/09546634.2016.1183763 |
| work_keys_str_mv | AT anwaralhammadi experienceandchallengesforbiologicuseinthetreatmentofmoderatetoseverepsoriasisinafricaandthemiddleeastregion AT afafalsheikh experienceandchallengesforbiologicuseinthetreatmentofmoderatetoseverepsoriasisinafricaandthemiddleeastregion AT alfredammoury experienceandchallengesforbiologicuseinthetreatmentofmoderatetoseverepsoriasisinafricaandthemiddleeastregion AT samerghosn experienceandchallengesforbiologicuseinthetreatmentofmoderatetoseverepsoriasisinafricaandthemiddleeastregion AT paologisondi experienceandchallengesforbiologicuseinthetreatmentofmoderatetoseverepsoriasisinafricaandthemiddleeastregion AT issamhamadah experienceandchallengesforbiologicuseinthetreatmentofmoderatetoseverepsoriasisinafricaandthemiddleeastregion AT abdulghanikibbi experienceandchallengesforbiologicuseinthetreatmentofmoderatetoseverepsoriasisinafricaandthemiddleeastregion AT khalidshirazy experienceandchallengesforbiologicuseinthetreatmentofmoderatetoseverepsoriasisinafricaandthemiddleeastregion |